Search
Alizapride
go.drugbank.com/drugs/DB01425InvestigationalAlizapride is a dopamine antagonist that is capable of demonstrating both prokinetic and antiemetic effects. This kind of pharmacological activity makes it effective for use in the treatment of various kinds of nausea and vomiting, inclu...
DPDPE
go.drugbank.com/drugs/DB08861ExperimentalA heterodetic cyclic peptide that is a cyclic enkephalin analogue, having D-penicillaminyl residues located at positions 2 and 5, which form the heterocycle via a disulfide bond.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeThiosalicylic acid
go.drugbank.com/drugs/DB14026ExperimentalSynonyms: o-Carboxythiophenol, o-Benzoic acid thiolCategories: Analgesics, Non-NarcoticANA975
go.drugbank.com/drugs/DB06490ExperimentalANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.
Synonyms: THIAZOLO(4,5-D)PYRIMIDIN-2(3H)-ONE, 5-AMINO-3-(2,3-DI-O-ACETYL-.BETA.-D-RIBOFURANOSYL)-CRx-119
go.drugbank.com/drugs/DB05688ExperimentalCRx-119 is a novel synergistic combination drug candidate discovered using the CombinatoRx combination High Throughput Screening (cHTS(TM)) technology with potential therapeutic use in a broad range of immuno-inflammatory conditions. CRx...
Plitidepsin
go.drugbank.com/drugs/DB04977InvestigationalAplidine is a peptide found in tunicates which shows promise in shrinking tumors in pancreatic, stomach, bladder, and prostate cancers. The specific marine organism is Aplidium albicans. Aplidine is also of interest as a potential treatm...
Toloxatone
go.drugbank.com/drugs/DB09245ExperimentalToloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeAd5-nCoV
go.drugbank.com/drugs/DB15655Investigational[L12675,L12678] It is being developed by CanSino Biologics Inc., in partnership with the Beijing Institute of Biotechnology, who in March 2020 announced the approval of a phase I clinical trial (ChiCTR2000030906
Romifidine
go.drugbank.com/drugs/DB11543ExperimentalVet approvedThis drug's chemical structure closely resembles that of clonidine, however, romifidine is not approved for use in humans.
QazCovid-in
go.drugbank.com/drugs/DB16441InvestigationalIt demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials[L30633, L30638].